#United States #New York #Securities Class #INOVIO Pharmaceuticals #Lead Plaintiff

Important Reminder for Investors

April 7, 2026, is an essential date for investors involved in the Inovio Pharmaceuticals, Inc. securities class action. Those interested in taking on the role of lead plaintiff must file their motions by this date to ensure their voices are heard in the litigation process. Failure to meet this deadline will result in the loss of the ability to direct the case and choose legal representation.

What is a Lead Plaintiff?

Under the Private Securities Litigation Reform Act of 1995 (PSLRA), the lead plaintiff is designated to represent the interests of the class members in a securities litigation. This individual or group is expected to effectively guide the case and make key decisions regarding its strategy and management.

Key Responsibilities of a Lead Plaintiff

A lead plaintiff is typically the individual or entity with the most substantial financial stake in the outcome of the class action. Their responsibilities include:

• - Directing litigation strategy: As a lead plaintiff, the appointed party plays a crucial role in outlining how the case will progress.
• - Selecting lead counsel: They have the authority to choose the legal team that will advocate on behalf of the class.

Interestingly, serving as a lead plaintiff entails no financial risk since attorneys usually operate on a contingency basis, meaning they are only paid if the case is successful. Thus, institutional investors often rise to this position in major securities class actions, ensuring that the litigation is managed by those fully invested in the outcome.

Timeline and Procedures

Post-deadline on April 7, 2026, motions for lead plaintiff will be reviewed by the court, which will appoint the most suitable candidate. Investors who do not seek lead plaintiff status but purchased INO securities during the defined class period—from October 10, 2023, to December 26, 2025—will still be considered class members and may benefit if the litigation yields favorable results.

Rights of Absent Class Members

For class members who opt not to pursue lead plaintiff status, there is no immediate action required. Instead, they will receive notice should the case reach a settlement or result in a judgment, along with instructions on how to file their claims.

The Allegations Against Inovio

The securities class action against Inovio asserts that the company, along with certain executives, made materially false and misleading statements about their medical device production and FDA approval processes during the relevant period. As Joseph E. Levi, Esq. highlights, the process of selecting a lead plaintiff is crafted to ensure that shareholders with significant stakes adequately represent the class's interests.

To begin the process of filing or to gather more information, interested parties can reach out to Joseph E. Levi at [email protected] or call him at (212) 363-7500.

In conclusion, the next few weeks are critical for potential lead plaintiffs as the April 7 deadline approaches. Investors must act quickly to protect their investments and ensure proper representation in this important class action.

For further inquiries regarding the Inovio Pharmaceuticals class action, contact Levi Korsinsky, LLP, a leading securities firm. A proactive approach could lead to better management of your interests in the ongoing lawsuit.

• ---

For More Information: Visit www.zlk.com or call (212) 363-7500.